scispace - formally typeset
D

Dean Fergusson

Researcher at Ottawa Hospital Research Institute

Publications -  725
Citations -  38672

Dean Fergusson is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 90, co-authored 655 publications receiving 32781 citations. Previous affiliations of Dean Fergusson include Children's Hospital of Eastern Ontario & Université de Montréal.

Papers
More filters
Journal ArticleDOI

Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research

Andrew I R Maas, +342 more
- 01 Dec 2017 - 
TL;DR: The InTBIR Participants and Investigators have provided informed consent for the study to take place in Poland.
Journal ArticleDOI

A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery

TL;DR: Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin, as compared with the lysine analogues, precludes its use in high-risk cardiac surgery.
Reference EntryDOI

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion

TL;DR: Data from the head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of reducing perioperative blood loss, but the differences were small.
Journal ArticleDOI

Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.

TL;DR: The limited published evidence supports the use of restrictive transfusion triggers in patients who are free of serious cardiac disease, however, most of the data on clinical outcomes were generated by a single trial.
Journal ArticleDOI

Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials

TL;DR: Based on the current clinical trials, MSC therapy appears safe, however, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.